Literature DB >> 27085541

Ten years of cerebral venous thrombosis: male gender and myeloproliferative neoplasm is associated with thrombotic recurrence in unprovoked events.

H Y Lim1,2, C Ng2, G Donnan3, H Nandurkar4,5, Prahlad Ho6,7,8,9.   

Abstract

Cerebral venous thrombosis (CVT) is a rare venous thrombotic event. We review our local experience in the management of CVT in comparison to other venous thromboembolism (VTE) with specific focus on risk factors for thrombotic recurrence. Retrospective evaluation of consecutive CVT presentations from January 2005 to June 2015, at two major tertiary hospitals in Northeast Melbourne, Australia. This population was compared to a separate audit of 1003 consecutive patients with DVT and PE. Fifty-two patients (30 female, 22 male) with a median age of 40 (18-83) years, presented with 53 episodes of CVT. Twenty-nine episodes (55 %) were associated with an underlying risk factor, with hormonal risk factors in females being most common. The median duration of anticoagulation was 6 months with 11 receiving life-long anticoagulation. Eighty-one percent had residual thrombosis on repeat imaging, which was not associated with recurrence at the same or distant site. Nine (17 %) had CVT-related haemorrhagic transformation with two resultant CVT-related deaths (RR 22.5; p = 0.04). All three VTE recurrences occured in males with unprovoked events (RR 18.2; p = 0.05) who were subsequently diagnosed with myeloproliferative neoplasm (MPN). Compared to the non-cancer VTE population, non-cancer CVT patients were younger, had similar rate of provoked events and VTE recurrence, although with significantly higher rate of MPN diagnosis (RR 9.30 (2.29-37.76); p = 0.002) CVT is a rare thrombotic disorder. All recurrences in this audit occurred in male patients with unprovoked events and subsequent diagnosis of MPN, suggesting further evaluation for MPN may be warranted in patients with unprovoked CVT.

Entities:  

Keywords:  Cerebral venous thrombosis; Male; Myeloproliferative neoplasm; Venous thrombosis

Mesh:

Substances:

Year:  2016        PMID: 27085541     DOI: 10.1007/s11239-016-1362-3

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  23 in total

Review 1.  Cerebral venous thrombosis.

Authors:  Gregory Piazza
Journal:  Circulation       Date:  2012-04-03       Impact factor: 29.690

Review 2.  Cerebral venous thrombosis: an update.

Authors:  Marie-Germaine Bousser; José M Ferro
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

Review 3.  Anticoagulation for cerebral venous sinus thrombosis.

Authors:  Jonathan M Coutinho; Sebastiaan F T M de Bruijn; Gabrielle deVeber; Jan Stam
Journal:  Stroke       Date:  2012-04       Impact factor: 7.914

4.  ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.

Authors:  F Rodeghiero; A Tosetto; T Abshire; D M Arnold; B Coller; P James; C Neunert; D Lillicrap
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

5.  Cerebral and sinus vein thrombosis.

Authors:  Stephan Moll; Beth Waldron
Journal:  Circulation       Date:  2014-08-19       Impact factor: 29.690

6.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J M Bamford; P A Sandercock; C P Warlow; J Slattery
Journal:  Stroke       Date:  1989-06       Impact factor: 7.914

7.  The JAK2 V617F mutation in patients with cerebral venous thrombosis.

Authors:  S M Passamonti; E Biguzzi; M Cazzola; F Franchi; F Gianniello; P Bucciarelli; D Pietra; P M Mannucci; I Martinelli
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

8.  Cerebral venous thrombosis in the absence of headache.

Authors:  Jonathan M Coutinho; Jan Stam; Patricia Canhão; Fernando Barinagarrementeria; Marie-Germaine Bousser; José M Ferro
Journal:  Stroke       Date:  2014-11-06       Impact factor: 7.914

9.  Cerebral sinus venous thrombosis: clinical and pathogenetic perspectives from Tuscany.

Authors:  Eva Terni; Nicola Giannini; Alberto Chiti; Gino Gialdini; Giovanni Orlandi; Vincenzo Montano; Daniele Orsucci; Marco Brondi; Ubaldo Bonuccelli; Michelangelo Mancuso
Journal:  Blood Coagul Fibrinolysis       Date:  2015-07       Impact factor: 1.276

10.  Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT).

Authors:  José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria
Journal:  Stroke       Date:  2004-02-19       Impact factor: 7.914

View more
  4 in total

Review 1.  Cerebral Venous Thrombosis: an Update.

Authors:  José M Ferro; Diana Aguiar de Sousa
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-23       Impact factor: 5.081

Review 2.  Cerebral venous thrombosis.

Authors:  Suzanne M Silvis; Diana Aguiar de Sousa; José M Ferro; Jonathan M Coutinho
Journal:  Nat Rev Neurol       Date:  2017-08-18       Impact factor: 42.937

3.  Towards the genetic basis of cerebral venous thrombosis-the BEAST Consortium: a study protocol.

Authors:  Ioana Cotlarciuc; Thomas Marjot; Muhammad S Khan; Sini Hiltunen; Elena Haapaniemi; Tiina M Metso; Jukka Putaala; Susanna M Zuurbier; Matthijs C Brouwer; Serena M Passamonti; Paolo Bucciarelli; Emanuela Pappalardo; Tasmin Patel; Paolo Costa; Marina Colombi; Patrícia Canhão; Aleksander Tkach; Rosa Santacroce; Maurizio Margaglione; Giovanni Favuzzi; Elvira Grandone; Donatella Colaizzo; Kostas Spengos; Antonio Arauz; Amanda Hodge; Reina Ditta; Stephanie Debette; Marialuisa Zedde; Guillaume Pare; José M Ferro; Vincent Thijs; Alessandro Pezzini; Jennifer J Majersik; Ida Martinelli; Jonathan M Coutinho; Turgut Tatlisumak; Pankaj Sharma
Journal:  BMJ Open       Date:  2016-11-22       Impact factor: 2.692

4.  Gender Differences in Risk Factor Profile and Clinical Characteristics in 89 Consecutive Cases of Cerebral Venous Thrombosis.

Authors:  Zoltan Bajko; Anca Motataianu; Adina Stoian; Laura Barcutean; Sebastian Andone; Smaranda Maier; Iulia-Adela Drăghici; Andrada Cioban; Rodica Balasa
Journal:  J Clin Med       Date:  2021-03-30       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.